Evidence map›Paper›PMID 37535402›Full record

ArticlemBio2023

Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern.

Ryan P McNamara, Jenny S Maron, Julie Boucau, Vicky Roy, Nicholas E Webb, Harry L Bertera, Amy K Barczak, The Positives Study Staff, Nicholas Franko, Jennifer K Logue and 10 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 1 country.

Ryan P McNamara *Ragon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.ORCID 0000-0002-8866-3532
Jenny S Maron *Ragon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.
Julie BoucauRagon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.ORCID 0000-0001-6731-7238
Vicky RoyRagon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.
Nicholas E WebbRagon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.
Harry L BerteraRagon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.
Amy K BarczakRagon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.ORCID 0000-0003-3806-2381
The Positives Study StaffDepartment of Medicine, Massachusetts General Hospital , Boston, Massachusetts, USA.
Nicholas FrankoDivision of Allergy and Infectious Diseases, University of Washington , Seattle, Washington, USA.
Jennifer K LogueDivision of Allergy and Infectious Diseases, University of Washington , Seattle, Washington, USA.
Megan KempDivision of Allergy and Infectious Diseases, University of Washington , Seattle, Washington, USA.
Jonathan Z LiHarvard Medical School , Boston, Massachusetts, USA.
Ling ZhouDepartment of Molecular Biosciences, University of Texas at Austin , Austin, Texas, USA.
Ching-Lin HsiehDepartment of Molecular Biosciences, University of Texas at Austin , Austin, Texas, USA.
Jason S McLellanDepartment of Molecular Biosciences, University of Texas at Austin , Austin, Texas, USA.ORCID 0000-0003-3991-542X
Mark J SiednerDepartment of Medicine, Massachusetts General Hospital , Boston, Massachusetts, USA.
Michael S SeamanHarvard Medical School , Boston, Massachusetts, USA.
Jacob E LemieuxDepartment of Medicine, Massachusetts General Hospital , Boston, Massachusetts, USA.
Helen Y ChuDivision of Allergy and Infectious Diseases, University of Washington , Seattle, Washington, USA.
Galit AlterRagon Institute of MGH, MIT, and Harvard , Cambridge, Massachusetts, USA.
Ragon Institute of MGH, MIT and Harvard · USUniversity of Washington · USThe University of Texas at Austin · USBrigham and Women's Hospital · USHarvard University · USBeth Israel Deaconess Medical Center · USBroad Institute · US

Funding

Specific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2019 to 2023
$40.0M
Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Kristian Graugaard Andersen · 2018 to 2026
$32.0M
Technology and Computational CoreP01AI165072 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI WESEMANN, DUANE R. · 2021 to 2023
$19.6M
Immunologic Signatures of SARS-CoV-2 Vaccination and DiseaseU01CA260476 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2020 to 2024
$3.7M
NCI NIH HHS U01 CA260476NIAID NIH HHS P01 AI165072NIAID NIH HHS U19 AI135995NIAID NIH HHS U19 AI142790
6 · The paper itself

Abstract

While immune correlates against SARS-CoV-2 are typically defined at peak immunogenicity following vaccination, immunologic responses that expand selectively during the anamnestic response following infection can provide mechanistic and detailed insights into the immune mechanisms of protection. Moreover, whether anamnestic correlates are conserved across variants of concern (VOC), including the Delta and more distant Omicron VOC, remains unclear. To define the anamnestic correlates of immunity, across VOCs, we deeply profiled the humoral immune response in individuals infected with sequence-confirmed Delta or Omicron VOC after completing the vaccination series. While limited acute N-terminal domain and receptor-binding domain (RBD)-specific immune expansion was observed following breakthrough infection, a significant immunodominant expansion of opsonophagocytic Spike-specific antibody responses focused largely on the conserved S2-domain of SARS-CoV-2 was observed. This S2-specific functional humoral response continued to evolve over 2-3 weeks following Delta or Omicron breakthrough, targeting multiple VOCs and common coronaviruses. Strong responses were observed on the fusion peptide (FP) region and the heptad repeat 1 (HR1) region adjacent to the RBD. Notably, the FP is highly conserved across SARS-related coronaviruses and even non-SARS-related betacoronavirus. Taken together, our results point to a critical role of highly conserved, functional S2-specific responses in the anamnestic antibody response to SARS-CoV-2 infection across VOCs. These humoral responses linked to virus clearance can guide next-generation vaccine-boosting approaches to confer broad protection against future SARS-related coronaviruses. IMPORTANCE The Spike protein of SARS-CoV-2 is the primary target of antibody-based recognition. Selective pressures, be it the adaption to human-to-human transmission or evasion of previously acquired immunity, have spurred the emergence of variants of the virus such as the Delta and Omicron lineages. Therefore, understanding how antibody responses are expanded in breakthrough cases of previously vaccinated individuals can provide insights into key correlates of protection against current and future variants. Here, we show that vaccinated individuals who had documented COVID-19 breakthrough showed anamnestic antibody expansions targeting the conserved S2 subdomain of Spike, particularly within the fusion peptide region. These S2-directed antibodies were highly leveraged for non-neutralizing, phagocytic functions and were similarly expanded independent of the variant. We propose that through deep profiling of anamnestic antibody responses in breakthrough cases, we can identify antigen targets susceptible to novel monoclonal antibody therapy or vaccination-boosting strategies.

Indexed as

COVID-19AntibodiesAntibodies, NeutralizingAntibodies, ViralBreakthrough InfectionsHumansSARS-CoV-2AntibodiesAntibodies, NeutralizingAntibodies, ViralantibodiesbreakthroughCOVID-19deltaomicronSARS-CoV-2vaccines

Identifiers

PMID37535402
PMCPMC10470538
OpenAlexW4385514758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.